Descripción del proyecto
Un análisis de orina sencillo para la detección temprana del cáncer de próstata
En Europa, el cáncer de próstata es el tipo de cáncer que se diagnostica con mayor frecuencia en los hombres. A pesar de la significativa carga para la salud pública, la detección tardía del cáncer de próstata avanzado sigue siendo un problema importante. Está creciendo la necesidad de programas de detección de cáncer de próstata basados en la población. El proyecto financiado con fondos europeos PROSTATOR desarrolla un análisis de orina fiable para el diagnóstico temprano del cáncer de próstata que no requiere biopsias innecesarias. El análisis indicará qué pacientes necesitan que se les realice una biopsia para determinar el tipo y el estadío del cáncer de próstata. El proyecto validará sus primeros resultados en una muestra amplia de 900 análisis de orina. Además de los biomarcadores que miden los análisis de orina comercializados, el proyecto ha identificado tres nuevos biomarcadores en todos los estadíos del cáncer.
Objetivo
Reliable urinary test for the diagnosis of prostate cancer Prostate cancer is a life threatening disease which affects about 400,000 males and causes 92,000 deaths per year in Europe. Among suspected cancer patients who undergo a prostate biopsy, only 45% really have a cancer. However, this diagnostic procedure is associated with discomfort, anxiety, bleeding, and the potential for serious infections requiring hospitalization. It is also very expensive. None of the tests available today offer an alternative which avoids unnecessary biopsies. To solve this problem we propose to validate a urinary, non-invasive, rapid and robust diagnostic test that we call PROSTATOR, for the early detection of prostate cancer without unnecessary biopsies. PROSTATOR quantifies three new prostate cancer specific biomarkers that we identified using our ERC Consolidator Grant. We show that, contrary to the biomarkers quantified by commercialized urinary tests for prostate cancer, our three new biomarkers were detected in all grades of tumours. Only cancer patients detected by our test will have a biopsy to determine the type and the grade of the prostate tumour but unnecessary biopsies will be avoided when the test is negative. Other advantages of our novel test: it can be performed from the first visit to the urologist, collecting the urine after prostatic massage and sending it to a laboratory that will give the diagnosis within 4 days. With this grant, we want to validate our first results on a large number of urines (900). We have established collaborations with Henri-Mondor and Foch hospitals to collect the urines and with the Genomic Platform of Institut Curie to quantify our biomarkers. We started discussions with tech transfer office of the Institut Curie to discuss the opportunity to license PROSTATOR to pharmaceutical companies that already confirmed their interest of our product, or create a start-up.
Ámbito científico
Programa(s)
Régimen de financiación
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotInstitución de acogida
75231 Paris
Francia